Impact of Prolonged Dual Antiplatelet Therapy After Bifurcation Percutaneous Coronary Intervention in Patients with High Ischemic Risk.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
accepted:
23
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
The aim of this study was to evaluate the impact of prolonged dual antiplatelet therapy (DAPT) on clinical outcomes in patients undergoing percutaneous coronary interventions (PCI) for bifurcation coronary lesions. A total of 1000 patients who underwent PCI for coronary bifurcation lesions and had clinical follow-up were divided into two groups based on the duration of DAPT: DAPT > 12 months and DAPT ≤ 12 months). Patients who experienced a myocardial infarction, required repeat PCI, or died within 1 year after the initial procedure were excluded. Among the 1000 eligible patients, 394 patients received DAPT for > 12 months (39.4%). Most patients in our study presented with chronic coronary disease (61%). The majority of patients in our study (62.8%) had a low bleeding risk. The median follow-up duration was 35 months (interquartile range 20.6-36.5). There were no significant differences in the major adverse cardiovascular events (MACE) between groups of prolonged DAPT (> 12 month) and DAPT ≤ 12 months (18.8% vs. 14.9%, p = 0.11). Patients with clinical features of high ischemic risk (HIR) had a significantly increased risk of MACE (hazard ratio [HR] 1.92, 95% confidence interval [CI] 1.12-3.26, p = 0.015) when compared with patients without clinical features of HIR. Compared with DAPT ≤ 12 months, extended DAPT (> 12 months) did not improve outcomes in patients with clinical (HR 1.24, 95% CI 0.90-1.72, p = 0.19) and technical features (HR 1.04, 95% CI 0.67-1.63, p = 0.85) of HIR. In this multicenter real-world registry, administration of DAPT for more than 12 months in patients who have undergone PCI for bifurcation lesion is not associated with a reduced incidence of MACE in long-term follow-up. ClinicalTrials.gov identifier no. NCT03450577.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate the impact of prolonged dual antiplatelet therapy (DAPT) on clinical outcomes in patients undergoing percutaneous coronary interventions (PCI) for bifurcation coronary lesions.
METHODS
METHODS
A total of 1000 patients who underwent PCI for coronary bifurcation lesions and had clinical follow-up were divided into two groups based on the duration of DAPT: DAPT > 12 months and DAPT ≤ 12 months). Patients who experienced a myocardial infarction, required repeat PCI, or died within 1 year after the initial procedure were excluded.
RESULTS
RESULTS
Among the 1000 eligible patients, 394 patients received DAPT for > 12 months (39.4%). Most patients in our study presented with chronic coronary disease (61%). The majority of patients in our study (62.8%) had a low bleeding risk. The median follow-up duration was 35 months (interquartile range 20.6-36.5). There were no significant differences in the major adverse cardiovascular events (MACE) between groups of prolonged DAPT (> 12 month) and DAPT ≤ 12 months (18.8% vs. 14.9%, p = 0.11). Patients with clinical features of high ischemic risk (HIR) had a significantly increased risk of MACE (hazard ratio [HR] 1.92, 95% confidence interval [CI] 1.12-3.26, p = 0.015) when compared with patients without clinical features of HIR. Compared with DAPT ≤ 12 months, extended DAPT (> 12 months) did not improve outcomes in patients with clinical (HR 1.24, 95% CI 0.90-1.72, p = 0.19) and technical features (HR 1.04, 95% CI 0.67-1.63, p = 0.85) of HIR.
CONCLUSION
CONCLUSIONS
In this multicenter real-world registry, administration of DAPT for more than 12 months in patients who have undergone PCI for bifurcation lesion is not associated with a reduced incidence of MACE in long-term follow-up.
REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier no. NCT03450577.
Identifiants
pubmed: 38871947
doi: 10.1007/s40256-024-00657-1
pii: 10.1007/s40256-024-00657-1
doi:
Banques de données
ClinicalTrials.gov
['NCT03450577']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826. https://doi.org/10.1093/eurheartj/ehad191 .
doi: 10.1093/eurheartj/ehad191
pubmed: 37622654
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407–77. https://doi.org/10.1093/eurheartj/ehz425 .
doi: 10.1093/eurheartj/ehz425
pubmed: 31504439
Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68:1851–64.
doi: 10.1016/j.jacc.2016.07.760
pubmed: 27595509
Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J. 2019;40(31):2595–604. https://doi.org/10.1093/eurheartj/ehz453 .
doi: 10.1093/eurheartj/ehz453
pubmed: 31397487
Shanmugam VB, Psaltis PJ, Tay L, et al. Procedural and clinical outcomes in management of bifurcationa lesions in ST elevation myocardial infarction. Heart Lung Circ. 2019. https://doi.org/10.1016/j.hlc.2019.01.011 .
doi: 10.1016/j.hlc.2019.01.011
Ninomiya K, Serruys PW, Garg S, et al. Predicted and observed mortality at 10 years in patients with bifurcation lesions in the SYNTAX trial. JACC Cardiovasc Interv. 2022;15:1231–42.
doi: 10.1016/j.jcin.2022.04.025
pubmed: 35595676
Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, Garg S, de Vries T, Garcia- Garcia HM, Onuma Y, de Winter RJ, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Meier B, Jüni P, Yazdani A, Copt S, Windecker S, Serruys PW. First generation versus second generation drug- eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv. 2016;87:E248–60.
doi: 10.1002/ccd.26344
pubmed: 26649651
Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–367.
doi: 10.1093/eurheartj/ehaa575
pubmed: 32860058
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.
doi: 10.1093/eurheartj/ehy394
pubmed: 30165437
Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–34.
doi: 10.1016/j.jacc.2016.02.064
pubmed: 27079334
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–69. https://doi.org/10.1093/eurheartj/ehy462 .
doi: 10.1093/eurheartj/ehy462
pubmed: 30165617
Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006. Circulation. 2007;115:2352–7. https://doi.org/10.1161/CIRCULATIONAHA.107.688416 .
doi: 10.1161/CIRCULATIONAHA.107.688416
pubmed: 17470710
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 .
doi: 10.1161/CIRCULATIONAHA.110.009449
pubmed: 21670242
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. https://doi.org/10.1056/NEJMoa1409312 .
doi: 10.1056/NEJMoa1409312
pubmed: 25399658
pmcid: 4481318
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800. https://doi.org/10.1056/NEJMoa1500857 .
doi: 10.1056/NEJMoa1500857
pubmed: 25773268
Rhee TM, Park KW, Kim CH, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. dual antiplatelet therapy duration determines outcome after 2—but not 1-stent strategy in left main bifurcation percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(24):2453–63. https://doi.org/10.1016/j.jcin.2018.09.020 .
doi: 10.1016/j.jcin.2018.09.020
pubmed: 30573055
Zimarino M, Angiolillo DJ, Dangas G, Capodanno D, Barbato E, Hahn JY, Giustino G, Watanabe H, Costa F, Cuisset T, Rossini R, Sibbing D, Burzotta F, Louvard Y, Shehab A, Renda G, Kimura T, Gwon HC, Chen SL, Costa RA, Koo BK, Storey RF, Valgimigli M, Mehran R, Stankovic G. Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. EuroIntervention. 2021;17(1):59–66. https://doi.org/10.4244/EIJ-D-20-00885 .
doi: 10.4244/EIJ-D-20-00885
pubmed: 32928716
pmcid: 9725001
Jang WJ, Ahn SG, Song YB, Choi SH, Chun WJ, Oh JH, Cho SW, Kim BS, Yoon JH, Koo BK, Yu CW, Jang YS, Tahk SJ, Kim HS, Gwon HC, Lee SY, Hahn JY. Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the Coronary Bifurcation Stenting Registry II. Circ Cardiovasc Interv. 2018;11(7): e005849. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005849 .
doi: 10.1161/CIRCINTERVENTIONS.117.005849
pubmed: 30006330
Cirillo P, Di Serafino L, Gamra H, Zimarino M, Barbato E, Briguori C, Amat-Santos IJ, Chieffo A, Erglis A, Gil RJ, Kedev SA, Petrov I, Radico F, Niglio T, Nakamura S, Costa RA, Kanic V, Perfetti M, Pellicano M, Maric K, Tesorio T, Vukcevic V, Esposito G, Stankovic G, EuroBifurcation Club. Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry. Panminerva Med. 2023;65(1):1–12. https://doi.org/10.23736/S0031-0808.22.04604-3 .
doi: 10.23736/S0031-0808.22.04604-3
pubmed: 35546730
Kogame N, Chichareon P, De Wilder K, Takahashi K, Modolo R, Chang CC, Tomaniak M, Komiyama H, Chieffo A, Colombo A, Garg S, Louvard Y, Jüni P, Steg PG, Hamm C, Vranckx P, Valgimigli M, Windecker S, Stoll HP, Onuma Y, Janssens L, Serruys PW. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheter Cardiovasc Interv. 2020;96:100–11.
doi: 10.1002/ccd.28428
pubmed: 31410968
Zimarino M, Briguori C, Amat-Santos IJ, Radico F, Barbato E, Chieffo A, Cirillo P, Costa RA, Erglis A, Gamra H, Gil RJ, Kanic V, Kedev SA, Maddestra N, Nakamura S, Pellicano M, Petrov I, Strozzi M, Tesorio T, Vukcevic V, De Caterina R, Stankovic G, EuroBifurcation Club. Mid-term outcomes after percutaneous interventions in coronary bifurcations. Int J Cardiol. 2019;283:78–83. https://doi.org/10.1016/j.ijcard.2018.11.139 .
doi: 10.1016/j.ijcard.2018.11.139
pubmed: 30528620
Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–49.
doi: 10.1001/jama.2016.3775
pubmed: 27022822
pmcid: 5408574
Wang HY, Wang Y, Yin D, Gao RL, Yang YJ, Xu B, Dou KF. Percutaneous coronary intervention complexity and risk of adverse events in relation to high bleeding risk among patients receiving drug-eluting stents: insights from a large single-center cohort study. J Interv Cardiol. 2020;25(2020):2985435. https://doi.org/10.1155/2020/2985435 .
doi: 10.1155/2020/2985435
Wang HY, Yin D, Zhao YY, Zhang R, Yang YJ, Xu B, Dou KF. Prognostic and practical validation of ESC/EACTS high ischemic risk definition on long-term thrombotic and bleeding events in contemporary PCI patients. J Atheroscler Thromb. 2022;29(4):502–26. https://doi.org/10.5551/jat.60129 .
doi: 10.5551/jat.60129
pubmed: 33746144
Yamamoto K, Watanabe H, Morimoto T, Obayashi Y, Natsuaki M, Domei T, Yamaji K, Suwa S, Isawa T, Watanabe H, Yoshida R, Sakamoto H, Akao M, Hata Y, Morishima I, Tokuyama H, Yagi M, Suzuki H, Wakabayashi K, Suematsu N, Inada T, Tamura T, Okayama H, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T, STOPDAPT-2 and STOPDAPT-2 ACS Investigators. Clopidogrel monotherapy after 1-month DAPT in patients with high bleeding risk or complex PCI. JACC Asia. 2023;3(1):31–46. https://doi.org/10.1016/j.jacasi.2022.09.011 .
doi: 10.1016/j.jacasi.2022.09.011
pubmed: 36873770
pmcid: 9982293
Apostolos A, Chlorogiannis D, Vasilagkos G, Katsanos K, Toutouzas K, Aminian A, Alexopoulos D, Davlouros P, Tsigkas G. Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: a systematic review and meta-analysis. Hellenic J Cardiol. 2023;71:33–41. https://doi.org/10.1016/j.hjc.2023.01.005 .
doi: 10.1016/j.hjc.2023.01.005
pubmed: 36736730
Genereux P, Giustino G, Redfors B, Palmerini T, Witzenbichler B, Weisz G, Stuckey TD, Maehara A, Mehran R, Kirtane AJ, Stone GW. Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. Int J Cardiol. 2018;268:61–7.
doi: 10.1016/j.ijcard.2018.03.103
pubmed: 30041804
Ueki Y, Karagiannis A, Zanchin C, Zanchin T, Stortecky S, Koskinas KC, Siontis GCM, Praz F, Otsuka T, Hunziker L, Heg D, Moschovitis A, Seiler C, Billinger M, Pilgrim T, Valgimigli M, Windecker S, Raber L. Validation of high-risk features for stent-related ischemic events as endorsed by the 2017 DAPT guidelines. JACC Cardiovasc Interv. 2019;12:820–30.
doi: 10.1016/j.jcin.2018.12.005
pubmed: 30981574